HomeDr. Enrico Pesenti, CEO of Accelera-a member of NMS Group, has co-authored the Article entitled “A tumor-in-host DEB-based approach for modeling cachexia and bevacizumab resistance” on the highly respected “Cancer Research” journal

Dr. Enrico Pesenti, CEO of Accelera-a member of NMS Group, has co-authored the Article entitled “A tumor-in-host DEB-based approach for modeling cachexia and bevacizumab resistance” on the highly respected “Cancer Research” journal

Nerviano, 13.12.2019

Dr. Enrico Pesenti, CEO of Accelera-a member of NMS Group, has co-authored the Article entitled “A tumor-in-host DEB-based approach for modeling cachexia and bevacizumab resistance” on the highly respected “Cancer Research” journal

Abstract: Adequate energy intake and homoeostasis are fundamental for the appropriate growth and maintenance of an organism; the presence of a tumor can break this equilibrium. Tumor energy requests can lead to extreme weight loss in animals and cachexia in cancer patients. Angiogenesis inhibitors, acting on tumor vascularization, counteract this tumor-host energy imbalance with significant results in preclinical models and more limited results in the clinic. Current pharmacokinetic-pharmacodynamic models mainly focus on the anti-angiogenic effects on tumor growth but do not provide information about host conditions. A model that can predict energetic conditions that provide significant tumor growth inhibition with acceptable host body weight reduction is therefore needed. We developed a new tumor-in-host Dynamic Energy Budget (DEB)-based model to account for the cytostatic activity of anti-angiogenic treatments. Drug effect was implemented as an inhibition of the energy fraction subtracted from the host by the tumor. The model was tested on seven xenograft experiments involving bevacizumab and three different tumor cell lines. The model successfully predicted tumor and host body growth data, providing a quantitative measurement of drug potency and tumor-related cachexia. The inclusion of a hypoxia-triggered resistance mechanism enabled investigation of the decreased efficacy frequently observed with prolonged bevacizumab treatments. In conclusion, the tumor-in-host DEB-based approach has been extended to account for the effect of bevacizumab. The resistance model predicts the response to different administration protocols and, for the first time, the impact of tumor-related cachexia in different cell lines. Finally, the physiological base of the model strongly suggests its use in translational human research.